COMMUNIQUÉS West-GlobeNewswire

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye [...]
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08/05/2024
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 [...]
Anika Announces CFO Transition
08/05/2024
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention [...]
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
08/05/2024
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context [...]
Cytek Biosciences Reports First Quarter 2024 Financial Results
08/05/2024
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first [...]
Supernus Announces First Quarter 2024 Financial Results
08/05/2024
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) [...]
Seer Reports First Quarter 2024 Financial Results
08/05/2024
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life [...]
Anika Reports First Quarter 2024 Financial Results
08/05/2024
Revenue up 7% on growing demand and favorable order timing; On-track for 2024 revenue guidance Cost reduction initiatives complete; On-track to achieve 2024 adjusted EBITDA guidance of $25-30 million, up over 75% at the [...]
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
08/05/2024
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of [...]
Terns Pharmaceuticals Announces Leadership Changes
08/05/2024
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
08/05/2024
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling [...]
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
08/05/2024
Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track [...]
RadNet Reports First Quarter Financial Results with Record First Quarter Revenue, Adjusted EBITDA(1) and Adjusted Earnings(3) and Revises Upwards 2024 Financial Guidance Ranges
08/05/2024
Total Company Revenue increased 10.5% to $431.7 million in the first quarter of 2024 from $390.6 million in the first quarter of 2023; Revenue from the Digital Health reportable segment increased 32.3% to $14.7 million [...]
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
08/05/2024
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on track to initiate by [...]
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
08/05/2024
-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company’s term loan by one year to September 30, 2026 -- -- Maintained full-year 2024 revenue [...]
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08/05/2024
SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a Surrozen antibody based [...]
electroCore Announces First Quarter 2024 Financial Results
08/05/2024
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08, 2024 (GLOBE [...]
Apollomics Announces Private Placement Financing and Addition to Board of Directors
08/05/2024
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment- [...]

Pages